Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis
about
Host pathogen relations: exploring animal models for fungal pathogensAdvances in the treatment of invasive neonatal candidiasisPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsNeutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseasesPharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infectionSafety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance.A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.Micafungin.Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.In vivo systematic analysis of Candida albicans Zn2-Cys6 transcription factors mutants for mice organ colonization.Antifungal pharmacodynamics: review of the literature and clinical applications.T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.Efficacy of micafungin alone or in combination against systemic murine aspergillosis.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisThe echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.New and emerging antifungal agents: impact on respiratory infections.Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsMicafungin: pharmacology, experimental therapeutics and clinical applications.Micafungin: the US perspective.Echinocandin antifungals: review and update.In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.Developments in the treatment of candidiasis: more choices and new challenges.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Antifungal prophylaxis following reduced-intensity stem cell transplantation.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Treatment of candiduria with micafungin: A case series.Micafungin for the prophylaxis and treatment of Candida infections.In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.Safety of micafungin in infants: insights into optimal dosing.Regulation of expression, activity and localization of fungal chitin synthases.Echinocandins: are they all the same?Nonclinical toxicological evaluation of occidiofungin, a unique glycolipopeptide antifungal.Echinocandins in antifungal pharmacotherapy.
P2860
Q26862890-D32E0846-8FF7-4DD3-B697-2FA11AC41A0BQ27022585-A72BC2E3-8331-464D-A3CB-E5D0F93D0A24Q27025299-4FF9BE94-ED8C-45EC-9C68-009A0888CCCBQ33236887-7059BBBD-A70A-455C-B01F-5A6F40B41743Q33722115-1687A858-D690-4EEA-9096-A117857F417CQ33883668-A2E6A1A0-C2C6-4C44-BCEA-0D4378DF7668Q33938201-590A6C88-C2E9-4A2B-9258-B59F66C239A3Q33940714-BA43959D-957D-47FB-9F5A-34FDFC146C7CQ33980368-B8421AD5-60CA-411F-BBEA-71762EA43190Q33980499-D7EF88E1-D65E-4EED-8B3B-5B755CD3409DQ33981019-EE39E2D9-8B60-4BF7-A64C-0B75440779FDQ33983499-90641ED4-4639-4B62-8F57-624BED212D44Q33983506-392D61C5-2181-4A8C-A159-EC5155AFD668Q34071444-763567F9-FC4B-4B30-91EF-D9567347D0C0Q34083129-40520E79-5667-44E9-877A-8DD8784EC368Q34108719-D766499E-8A8A-4D9A-AECF-CAC2C9C2022AQ34108880-3F3B78B1-0042-4287-A42F-9091765354C8Q34881309-89B3F3C0-D4AF-4AEB-8E1F-ACC310DB988EQ34884594-DE5BE1B5-0E24-4A9C-9C86-644429E549BBQ35026516-778FCC12-B2D2-4A71-B7BE-939438CFF36CQ35185757-8FF20D9D-70F4-4B56-9783-CEE3579A79FFQ35627629-5BF64996-54BE-42DD-9701-EDFFD39950C6Q35635928-AE265AFA-B522-43A7-A820-E73232476A9BQ36120798-1F3C0A35-5D9D-4C51-B75F-27FE371063F4Q36140652-AA188DAA-1A33-484B-A002-E69205E528B8Q36441524-95690FCC-D521-491B-9001-5AB690361E76Q36538739-C3D94281-102D-48A4-92EF-94ADE8523A7DQ36623050-98473939-DA18-4187-90B4-A35A25ED34B9Q36626518-19C101D5-85B7-4425-B00E-8A6413C60A54Q36658236-1F05C57A-FFD7-4D91-946B-FD360ED3B439Q36828156-67F78A10-31F3-4467-B8A8-B5AF70C1D625Q36871028-19E726F1-FAE4-4A4E-9712-00A289E211F9Q37124868-78055ED0-CC04-4B2B-998E-7D031DA5D8F7Q37505132-4E22C3F2-F106-4095-BB56-8E6487880E65Q37625016-F2143243-6B22-4450-96D9-C0B55E0714B3Q37827883-C75D36EA-A1E5-4F43-937D-5E95A4680C6FQ37869907-87544F1C-C2B5-4A78-990F-98B6CEDA0657Q37974743-5AD986A5-4596-4862-8B45-D9FF7BF2EDDCQ39332767-C76BB037-CA5A-45C7-B400-953362488394Q39458862-9D7FC068-FE8E-408D-B163-5B6943DE8D21
P2860
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@ast
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@en
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@nl
type
label
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@ast
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@en
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@nl
prefLabel
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@ast
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@en
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@nl
P2093
P2860
P1476
Efficacy of FK463, a new lipop ...... candidiasis and aspergillosis
@en
P2093
F Matsumoto
S Kuwahara
S Matsumoto
Y Watanabe
P2860
P356
10.1128/AAC.44.3.614-618.2000
P407
P577
2000-03-01T00:00:00Z